When to Start SGLT2 Inhibitors in CKD
Start an SGLT2 inhibitor immediately when eGFR is ≥20 mL/min/1.73 m² in any adult with CKD who has either albuminuria ≥200 mg/g or clinically evident heart failure, regardless of diabetes status. 1
eGFR Thresholds for Initiation
Do not start SGLT2 inhibitors when eGFR is <20 mL/min/1.73 m² – this is a firm cutoff for new initiation based on KDIGO 2024 guidelines (1A recommendation). 1
Between eGFR 20–29 mL/min/1.73 m² (CKD Stage 4), initiation is strongly recommended (1A) if the patient meets either criterion:
- Urine albumin-to-creatinine ratio (UACR) ≥200 mg/g (approximately ≥20 mg/mmol), or
- Clinically evident heart failure 1
Above eGFR 30 mL/min/1.73 m² (CKD Stages 1–3), initiate SGLT2 inhibitors broadly in patients with CKD, particularly when albuminuria is present or cardiovascular risk is elevated. 2, 3
Albuminuria-Based Decision Making
UACR ≥200 mg/g is the strong threshold for initiating SGLT2 inhibitors in CKD Stage 4 (eGFR 20–29). 1
UACR <200 mg/g but with progressive CKD (declining eGFR trajectory over time) warrants consideration for initiation, though this carries a weaker recommendation (2B). 1
In earlier CKD stages (eGFR ≥30), even lower levels of albuminuria support SGLT2 inhibitor use as part of foundational CKD therapy. 4, 3
Timing Relative to Other Therapies
SGLT2 inhibitors should be co-first-line therapy with RAS inhibitors – you do not need to complete RAS inhibitor dose titration before starting an SGLT2 inhibitor. 4
In fact, adding an SGLT2 inhibitor may facilitate maintaining or up-titrating RAS inhibitor doses by stabilizing hemodynamics and kidney function. 4
Early initiation is key – starting SGLT2 inhibitors promptly, even during hospitalization for CKD-related complications or heart failure, maximizes long-term kidney and cardiovascular protection. 5, 6
Diabetes Status: Irrelevant to the Decision
CKD indication for SGLT2 inhibitors applies equally to patients with and without type 2 diabetes. 1, 3
The kidney and cardiovascular benefits are independent of glucose-lowering effects. 2, 7
Continuation Strategy After Initiation
Once started, continue SGLT2 inhibitors even if eGFR falls below 20 mL/min/1.73 m² – the safety and efficacy profile differs for continuation versus new initiation. 1
Stop only at dialysis initiation or kidney transplantation, not at any specific eGFR threshold. 1
Monitoring and Safety
Expect a modest initial eGFR drop of 3–5 mL/min/1.73 m² within the first weeks – this is a hemodynamic effect, not kidney injury, and does not require discontinuation or intensified monitoring. 1
Standard CKD monitoring intervals (e.g., quarterly labs) are sufficient – no extra frequency is needed solely because of SGLT2 inhibitor use. 1
When combining with RAS inhibitors, check potassium and creatinine 2–4 weeks after starting the SGLT2 inhibitor to ensure stability. 1
Temporarily withhold during prolonged fasting, before surgery, or in critical illness to reduce ketosis risk, regardless of baseline eGFR. 1
Populations Where Standard Recommendations Do Not Apply
Kidney transplant recipients – guideline recommendations are not intended for this group. 1
Polycystic kidney disease – specific guidance is lacking. 1
Rare kidney diseases (>150 conditions per KDIGO) – insufficient evidence for routine use. 1
Patients already on dialysis – landmark trials excluded this population, though emerging data suggest potential cardiovascular benefits; large-scale trials are ongoing. 8
Common Pitfalls to Avoid
Do not delay initiation waiting for "optimal" RAS inhibitor dosing – start both agents together or in rapid sequence. 4
Do not stop SGLT2 inhibitors due to the expected initial eGFR dip – this is physiologic and protective long-term. 1
Do not withhold in advanced CKD (eGFR 20–29) if the patient meets albuminuria or heart failure criteria – the evidence for benefit is strongest in this high-risk group. 1, 7
Do not assume SGLT2 inhibitors are only for diabetes – the CKD indication is diabetes-independent. 1, 3